StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.44+0.03 (+2.13%)

Close on Nov 18, 2026Market cap $14.32MP/E –Yield –

Seres Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Seres Therapeutics's pe ratio was 11.5× on Apr 30, 2026, against 617.0× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202611.5×−13.7
2025Dec 31, 202525.2×–

More Seres Therapeutics figures

See a number that looks wrong?